ReviewFrontiers in medicine2025
The latest research progress on the clinical application of nemonoxacin.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Some Newer Antibiotics Active AgainstAntibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nemonoxacin is a novel non-fluorinated quinolone antibacterial agent, characterized by a broad antibacterial spectrum, strong antibacterial activity, low protein binding rate, high oral bioavailability, and extensive tissue distribution. Its unique pharmacological properties confer high clinical application value. In the context of bacterial resistance, this article aims to provide a comprehensive review of nemonoxacin's antibacterial activity, immunomodulatory effects, and its application in infectious diseases as well as in patients with hepatic or renal insufficiency, with the goal of offering more drug options for clinical treatment and providing a reference for future clinical research and widespread application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.